CONTROL PUMA-NER-6201
Clinical Trial Program
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide
Phase II
Status
Recruiting
Tumour subtype:
HER2+
Scenario
Adjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Carlos Barcenas, MD, MSc (The University of Texas MD Anderson Cancer Center Houston, TX)
